Income Statement Presentation 2023

Multiple Sclerosis: Global leader, reaching 21% patient share Ph Ill results for 6M SC Ocrevus expected in 2023 Roche CHFM 1,750 1,500 1,250 +55% +10% 1,000 750 500 250 +25% YoY CER growth • +18% Q4 19 Q4 20 Q4 21 Q4 22 ■ US ■ Europe International Q4 update • #1 treatment in US and EU-5, both in total share and new to brand share Higher retention rate than other MS medicines Outlook 2023 • US/EU: Further market share gains expected ⚫ Ph III (OCARINA II) Ocrevus SC with Q6M dosing in RMS & PPMS data read out expected . Ph III (GAVOTTE/MUSETTE) high-dose Ocrevus nearing recruitment completion in Q1 CER=Constant Exchange Rates; MS-multiple sclerosis; SC=subcutaneous; Q6M-every 6 months; RMS=relapsing MS; PPMS-primary progressive MS 29

View entire presentation